Proper diagnosis and effective monitoring of patients with mitochondrial diseases remains a challenge in part because plasma and urine metabolite concentrations are nonspecific, tissue biopsies have limited acceptability and are prone to sampling error, and longitudinal measurements with invasive procedures are difficult.^[@R1]^

MELAS syndrome (mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes) is a maternally inherited and relatively prevalent mitochondrial disorder. Multiple studies have reported magnetic resonance spectroscopy (MRS) findings in the brain including elevated lactate, but studies of metabolism in skeletal muscle by MRS methods have been limited. For example, a combined examination with ^31^P and ^1^H NMR spectroscopy has characterized mitochondrial function and intramyocellular lipids (IMCLs) in one individual with MELAS.^[@R2]^ This study points to the advantages of MRS in examinations of patients with suspected mitochondrial disorders---subject acceptability, safety, and detailed metabolic information specific to an organ.

The purpose of this study was to examine the feasibility of ^1^H MRS at 7 Tesla (7T) in MELAS participants and maternal relatives. We separately determined normal IMCL in healthy controls; results were compared with an earlier cohort of healthy controls. In MELAS, a robust correlation was found between IMCL abundance and percent A3243G mutant mitochondrial DNA (mtDNA) abundance in the blood. The study was well tolerated by all participants. The high chemical shift dispersion at 7T was advantageous because the IMCL and other metabolite signals were easily resolved. Thus, ^1^H MRS at 7T may provide an avenue for investigating disease severity as well as the response of skeletal muscle to therapies.

METHODS {#s1}
=======

Standard protocol approvals, registrations, and patient consents. {#s1-1}
-----------------------------------------------------------------

This study was approved by the Institutional Review Board of the University of Texas Southwestern Medical Center. Informed written consent was obtained from all participants or their legal guardians as appropriate. They were studied over 4 months in one visit (each lasting less than 3 hours).

General methods. {#s1-2}
----------------

Mutant mtDNA abundance (expressed as percent of mutant DNA relative to total blood DNA) was routinely determined in the blood by quantitative PCR. Because mutation abundance can vary with age by 0.6%--1.9% per year in each person, participants were genotyped within 3 years preceding enrollment. All participants\' symptoms and medical history were obtained using a standardized questionnaire. Complete hematologic, endocrine, chemical, and lipid profiles (including blood cell count, blood electrolytes, transaminases, lactate, urea nitrogen, creatinine, amino acids, creatine kinase, free fatty acids, thyroid-stimulating hormone, T4, lipid panel \[total, low-density lipoprotein and high-density lipoprotein cholesterol, and triglycerides\], fasting blood glucose, and hemoglobin A1c \[HbA1c\]) were measured by standard clinical laboratory methods and compared with normal values established in each laboratory.

Skeletal muscle proton MRS. {#s1-3}
---------------------------

The details of the examination have been published. Briefly, leg calf muscles of rested (\>2 hours) participants were subject to MRS in a 7T system (Achieva; Philips Medical Systems, Cleveland, OH) without sedation. Scan sessions lasted less than 1 hour. Participants were positioned supine with their legs parallel to the magnetic field and the left calf sitting on the center of a partial volume quadrature transmit/receive coil customized to fit the shape of a human calf. Axial, coronal, and turbo spin-echo images were first acquired to guide voxel placement within the soleus muscle. Single-voxel ^1^H MRS spectra were collected from the soleus with a volume of 3--5 mL, using a STimulated Echo Acquisition Mode (STEAM) sequence, at long echo time (TE) of both 140 and 280 milliseconds, and a constant repetition time of 2 seconds. A typical number of scans were 192 (or 6.4 minutes for TE 140 milliseconds) and 256 (or 8.5 minutes for TE 280 milliseconds). No water suppression pulses were applied during data acquisition to avoid signal reduction due to possible magnetization-transfer effects on metabolites as we previously described.^[@R3]^ The ^1^H chemical shifts of all metabolite resonances arising from muscle were referenced to creatine methyl protons set to 3.02 parts per million (ppm) (Cr3). The area of each metabolite ^1^H resonance signal was determined by fitting the spectrum to a Voigt lineshape (variable proportions of lorentzian plus gaussian) using ACD software (Advanced Chemistry Development, Inc., Toronto, ON, Canada). The asymmetry of the extramyocellular lipid signal was fitted by 2 Voigt lineshapes as described.^[@R3]^ For quantitative comparison between the metabolites, the area of creatine methyl ^1^H resonance signal (Cr3) was used as the internal standard (30 mmol/kg wet tissue weight). All MRS data quantifications are expressed in millimoles per kilogram wet tissue weight. Errors denote mean ± SD where indicated.

RESULTS {#s2}
=======

All the participants tested positive for the m.3243A\>G mutation except those identified as maternal relatives ([table](#T1){ref-type="table"}). As a group, the MELAS participants exhibited the common features of the disorder such as lactic acidosis, stroke-like episodes, hearing loss, neuropathy and, in some, diabetes as indicated in the [table](#T1){ref-type="table"}. Elevated IMCLs were observed in all the MELAS participants examined by MRS ([figure 1](#F1){ref-type="fig"}). Of the 8 participants with MELAS ([table](#T1){ref-type="table"}), the average concentration of IMCLs was 26 ± 18 mmol/kg muscle mass. The average concentration of IMCL among participants with the more severe phenotype (participants 4, 7, 8, and 10) tended to be higher, 33 mmol/kg muscle mass. The association between IMCL abundance and percent mutant mtDNA abundance depended on the coexistence of diabetes ([figure 2](#F2){ref-type="fig"}).

###### 

Characteristics of the participants and IMCL values
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![Proton spectra of skeletal muscle\
MRS of 2 soleus muscles (participants 1 \[A\] and 2 \[B\]). Proton spectra were acquired at 2 echo times as described in the text. Solid black lines are plots of the spectra. IMCL CH2 represents resonances attributed to intramyocellular lipids, whereas EMCL CH2 is considered to arise from extramyocellular lipids. Carnitine CH3 = signal arising from carnitine; creatine CH3 = signal emanating from carbon 3 of creatine; H2O = water spectrum; MRS = magnetic resonance spectroscopy; ppm = parts per million.](NG2017005074FF1){#F1}

![IMCL, mtDNA, and diabetes correlations\
IMCL abundance correlations with percent mutant mtDNA (m.A3243G) in the blood. (A) Correlations for nondiabetic (i.e., HbA1c \<6% and no history of diabetes) participants. (B) Correlations for diabetic participants (HbA1c \>6% and a history of diabetes). Correlation coefficients with a straight line are given in each panel. IMCL = intramyocellular lipid; mtDNA, mitochondrial DNA.](NG2017005074FF2){#F2}

The ratio of the trimethylamine signal from carnitine at 3.20 ppm relative to the creatine methyl signal at 3.02 ppm (carnitine/Cr3) is typically \<1 or ∼1; the relative signals are sensitive to acquisition conditions. With a TE of 140 milliseconds, the signals are typically ∼1:1 or nearly equally sized "twin peaks." MELAS participants displayed significantly higher trimethylamine/Cr3 ratio (1.46 ± 0.40).

The relation between IMCL and plasma lactate, urea nitrogen, creatinine, free fatty acids, triglycerides, and total cholesterol was also examined. No significant correlation was found.

DISCUSSION {#s3}
==========

There is a paucity of biomarkers and of noninvasive methods available for the study of mitochondrial disorders. These obstacles limit clinical trials. For example, our study of dichloroacetate (a lactate-reducing drug) in a mitochondrial disorder was discontinued when toxic neuropathy was detected by nerve conduction monitoring despite the appearance of subjective benefits such as increased physical endurance. A key limitation is the difficulty of acquiring objective measurements of metabolic efficacy in the target tissue.^[@R4]^

Our study demonstrated an increase in the concentration of IMCLs among participants with MELAS syndrome compared with historical healthy controls. A simple explanation is that skeletal mitochondrial function in MELAS is substantially impaired, resulting in diminished oxidation of fatty acids and accumulation of IMCL in the cytosol.^[@R5]^ Among the cytoplasmic lipids that accumulate in relation to metabolic dysfunction are diacylglycerol and ceramide. Extensive evidence links these lipids with human mitochondrial dysfunction and with mitochondrial-related insulin resistance. For example, in diabetes, slowed postexercise mitochondrial adenosine triphosphate (ATP) resynthesis is related to increased insulin resistance,^[@R6]^ whereas insulin-stimulated rates of mitochondrial ATP synthesis are reduced in otherwise healthy insulin-resistant participants.^[@R7]^ Accumulation of these lipids has also been observed by MRS in relation to insulin resistance in otherwise healthy^[@R8],[@R9]^ and diabetic participants. An earlier case report did not find a significant increase in IMCL in a single participant using skeletal water as an internal reference and a TE of 30 milliseconds.^[@R2]^ This study used relatively long echo times to suppress water signal, so differences in acquisition and quantitation methods may be important.

This study found an unexpected increase in the carnitine/creatine ratio. Because this MRS method only detects the ratio of NMR-visible metabolites and not absolute concentration, this altered ratio could be due to some combination of altered relaxation times, increased carnitine, decrease creatine, or some combination of these factors. Further studies will clarify any potential racial differences in IMCL abundance in relation to insulin resistance^[@R10]^ in MELAS and the presence of IMCL in other mitochondrial diseases.
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